LEADER 04281oam 2200805 450 001 9910418354703321 005 20230621135401.0 010 $a3-030-41480-9 024 7 $a10.1007/978-3-030-41480-1 035 $a(CKB)4100000011392509 035 $a(DE-He213)978-3-030-41480-1 035 $a(MiAaPQ)EBC6310312 035 $a(Au-PeEL)EBL6310312 035 $a(OCoLC)1243532476 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/35896 035 $a(EXLCZ)994100000011392509 100 $a20200818h20212021 fy 0 101 0 $aeng 135 $aurmn#---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHuman challenge studies in endemic settings $eethical and regulatory issues /$fEuzebiusz Jamrozik, Michael J. Selgelid 210 $cSpringer Nature$d2021 210 1$aCham, Switzerland :$cSpringer Nature Switzerland AG :$cImprint: SpringerOpen,$d[2021] 210 4$dİ2021 215 $a1 online resource (xvii, 134 pages) $cillustrations; PDF, digital file(s) 225 1 $aSpringerBriefs in Ethics,$x2211-8101 311 08$aPrint version: 9783030414795 320 $aIncludes bibliographical references. 327 $a1. Introduction -- 2. Methods -- 3. History of human challenge studies -- 4. ethical issues -- 5. Community engagement, ethics review, and regulation -- 6. Case studies -- 7. Conclusions -- Acknowledgements. . 330 $aThis open access book provides an extensive review of ethical and regulatory issues related to human infection challenge studies, with a particular focus on the expansion of this type of research into endemic settings and/or low- and middle-income countries (LMICs). Human challenge studies (HCS) involve the intentional infection of research participants, and this type of research is rapidly increasing in frequency worldwide. HCS are widely considered to be an especially promising approach to vaccine development, including for pathogens endemic to LMICs. However, challenge studies are sometimes controversial and raise complex ethical issues, some of which are especially salient in endemic and/or LMIC settings. Informed by qualitative interviews with experts in infectious diseases and bioethics, this book highlights areas of ethical consensus and controversy concerning this kind of research. As the first volume to focus on ethical issues associated with human challenge studies, it sets the agenda for further work in this important area of global health research; contributes to current debates in research ethics; and aims to inform regulatory policy and research practice. Insofar as it focuses on HCS in (endemic) settings where diseases are present and/or widespread, much of the analysis provided here is directly relevant to HCS involving pandemic diseases including COVID19. 410 0$aSpringerBriefs in Ethics,$x2211-8101. 606 $aBioethics 606 $aInfectious diseases 606 $aVaccines 606 $aEconomic development 610 $aBioethics 610 $aInfectious Diseases 610 $aVaccine 610 $aDevelopment and Health 610 $aMoral Philosophy and Applied Ethics 610 $aInternal Medicine 610 $aPharmacology 610 $aDevelopment Studies 610 $ahuman challenge studies 610 $aOpen Access 610 $acapacity building in low-income countries 610 $acapacity building in middle-income countries 610 $amalariotherapy 610 $aintentional infection 610 $aethics of challenge studies 610 $achallenge studies in endemic settings 610 $achallenge studies and vulnerable populations 610 $aFalciparum malaria challenge studies in Africa 610 $aInfectious & contagious diseases 610 $aImmunology 610 $aDevelopment studies 615 0$aBioethics. 615 0$aInfectious diseases. 615 0$aVaccines. 615 0$aEconomic development. 676 $a171.7 700 $aJamrozik$b Euzebiusz$0899608 702 $aSelgelid$b Michael J. 801 2$bUkMaJRU 906 $aBOOK 912 $a9910418354703321 996 $aHuman challenge studies in endemic settings$92010023 997 $aUNINA